These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37560506)

  • 1. Topical Application of a Formulation Containing Pea Proteins and Xyloglucan in Adult Patients with Atopic Dermatitis: A Double-blind, Parallel, Randomized, Placebo-controlled, Multicenter Study.
    Sowlati M; Orzan OA; Morariu SH; Etropolska Z; Veraldi S; Dimitrov S
    J Clin Aesthet Dermatol; 2023 Jul; 16(7):35-41. PubMed ID: 37560506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Tolerability of a Novel Topical Treatment Containing Pea Protein and Xyloglucan in the Management of Atopic Dermatitis in Children: A Prospective, Multicenter Clinical Study.
    Sowlati M; Morariu SH; Orzan O; Veraldi S; Dodiuk-Gad RP; Orasan RI; Gainaru C
    Dermatol Ther (Heidelb); 2023 Nov; 13(11):2669-2679. PubMed ID: 37740857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study.
    Eichenfield LF; Gower RG; Xu J; Alam MS; Su JC; Myers DE; Sanders P; Vlahos B; Zang C; Lan J; Werth J
    Am J Clin Dermatol; 2023 Jul; 24(4):623-635. PubMed ID: 37184828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial.
    Simpson EL; Silverberg JI; Thyssen JP; Viguier M; Thaçi D; de Bruin-Weller M; Weidinger S; Chan G; DiBonaventura M; Biswas P; Feeney C; Koulias C; Cork MJ
    Am J Clin Dermatol; 2023 Jul; 24(4):609-621. PubMed ID: 37213005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI
    Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial.
    Ständer S; Kwatra SG; Silverberg JI; Simpson EL; Thyssen JP; Yosipovitch G; Zhang F; Cameron MC; Cella RR; Valdez H; DiBonaventura M; Feeney C
    Am J Clin Dermatol; 2023 Jan; 24(1):97-107. PubMed ID: 36512175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of a Product Containing Xyloglucan and Pea Protein on a Murine Model of Atopic Dermatitis.
    Campolo M; Casili G; Paterniti I; Filippone A; Lanza M; Ardizzone A; Scuderi SA; Cuzzocrea S; Esposito E
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32438777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children.
    Wahn U; Bos JD; Goodfield M; Caputo R; Papp K; Manjra A; Dobozy A; Paul C; Molloy S; Hultsch T; Graeber M; Cherill R; de Prost Y;
    Pediatrics; 2002 Jul; 110(1 Pt 1):e2. PubMed ID: 12093983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topical tacrolimus for atopic dermatitis.
    Cury Martins J; Martins C; Aoki V; Gois AF; Ishii HA; da Silva EM
    Cochrane Database Syst Rev; 2015 Jul; 2015(7):CD009864. PubMed ID: 26132597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical Trial.
    Eichenfield LF; Flohr C; Sidbury R; Siegfried E; Szalai Z; Galus R; Yao Z; Takahashi H; Barbarot S; Feeney C; Zhang F; DiBonaventura M; Rojo R; Valdez H; Chan G
    JAMA Dermatol; 2021 Oct; 157(10):1165-1173. PubMed ID: 34406366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crisaborole Topical Ointment, 2% in Adults With Atopic Dermatitis: A Phase 2a, Vehicle-Controlled, Proof-of-Concept Study.
    Murrell DF; Gebauer K; Spelman L; Zane LT
    J Drugs Dermatol; 2015 Oct; 14(10):1108-12. PubMed ID: 26461821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
    Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B
    Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials.
    Griffiths C; de Bruin-Weller M; Deleuran M; Fargnoli MC; Staumont-Sallé D; Hong CH; Sánchez-Carazo J; Foley P; Seo SJ; Msihid J; Chen Z; Cyr SL; Rossi AB
    Dermatol Ther (Heidelb); 2021 Aug; 11(4):1357-1372. PubMed ID: 34142350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of whey associated with dodder seed extract on moderate-to-severe atopic dermatitis in adults: A randomized, double-blind, placebo-controlled clinical trial.
    Mehrbani M; Choopani R; Fekri A; Mehrabani M; Mosaddegh M; Mehrabani M
    J Ethnopharmacol; 2015 Aug; 172():325-32. PubMed ID: 26151244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.
    Guttman-Yassky E; Teixeira HD; Simpson EL; Papp KA; Pangan AL; Blauvelt A; Thaçi D; Chu CY; Hong HC; Katoh N; Paller AS; Calimlim B; Gu Y; Hu X; Liu M; Yang Y; Liu J; Tenorio AR; Chu AD; Irvine AD
    Lancet; 2021 Jun; 397(10290):2151-2168. PubMed ID: 34023008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new topical treatment of atopic dermatitis in pediatric patients based on Ficus carica L. (Fig): A randomized, placebo-controlled clinical trial.
    Abbasi S; Kamalinejad M; Babaie D; Shams S; Sadr Z; Gheysari M; Askari VR; Rakhshandeh H
    Complement Ther Med; 2017 Dec; 35():85-91. PubMed ID: 29154073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of five patient-reported outcomes for atopic dermatitis severity in adults.
    Silverberg JI; Margolis DJ; Boguniewicz M; Fonacier L; Grayson MH; Ong PY; Fuxench ZC; Simpson EL
    Br J Dermatol; 2020 Jan; 182(1):104-111. PubMed ID: 30972740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of efficacy and safety of Lactobacillus rhamnosus in children aged 4-48 months with atopic dermatitis: An 8-week, double-blind, randomized, placebo-controlled study.
    Wu YJ; Wu WF; Hung CW; Ku MS; Liao PF; Sun HL; Lu KH; Sheu JN; Lue KH
    J Microbiol Immunol Infect; 2017 Oct; 50(5):684-692. PubMed ID: 26733351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of daily use of emollient 'plus' on corticosteroid consumption in patients with atopic dermatitis: An open, randomized controlled study.
    Zelenkova H; Kerob D; Salah S; Demessant-Flavigny AL
    J Eur Acad Dermatol Venereol; 2023 Jun; 37 Suppl 5():27-34. PubMed ID: 37092256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country, double-blind, randomized, placebo-controlled trial (the ETAC trial) over 18 months.
    Diepgen TL;
    Pediatr Allergy Immunol; 2002 Aug; 13(4):278-86. PubMed ID: 12390444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.